产品编号 :
Cas No. :
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 1mg | 95% | 询价 | |||
| 5mg | 95% | 询价 | |||
| 10mg | 95% | 询价 | |||
| 50mg | 95% | 询价 | |||
| 100mg | 95% | 询价 | |||
| 250mg | 95% | 询价 | |||
| 1g | 95% | 询价 |
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 1mg | 95% | 询价 | |||
| 5mg | 95% | 询价 | |||
| 10mg | 95% | 询价 | |||
| 50mg | 95% | 询价 | |||
| 100mg | 95% | 询价 | |||
| 250mg | 95% | 询价 | |||
| 1g | 95% | 询价 |
CAS No. |
34080-08-5 |
|---|---|
英文名称 |
(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol |
别名 |
(20S)-Protopanaxatriol, >98%;20(S)-Protopanaxatriol 34080-08-5;PROTOPANAXTRIOL;PROTOPANAXADIOL(RG);Protopanaxtriol ,98%;20(S)-Protopanaxtriol(PPT);20(S)-Protopanaxtriol;(20S)-5α-Dammar-24-ene-3β,6α,12β,20-tetrol |
标准英文名 |
(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol |
分子式 |
C30H52O4 |
分子量 |
476.74 |
精确分子量 |
476.39 |
SMILES |
CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@]12C |
标准SMILES |
CC1(C)[C@@H]2[C@@H](O)C[C@]3(C)[C@H](C[C@@H](O)[C@@H]4[C@H](CC[C@@]34C)[C@@](C)(O)CCC=C(C)C)[C@@]2(C)CC[C@@H]1O |
用途 |
(20S)-Protopanaxatriol is used for content determination, identification, and pharmacological studies; it is a metabolite of ginsenosides. Pharmacologically, protopanaxatriol-type saponins can synergistically promote antigen-loaded dendritic cell maturation from murine bone marrow cells in vitro, exerting specific cytotoxic effects against tumor cells. Additionally, PPT-type saponin injections significantly ameliorate hemiplegic symptoms, reduce cerebral infarct volume, and alleviate brain edema in rats with middle cerebral artery occlusion (MCAO). |
InChIKey |
SHCBCKBYTHZQGZ-CJPZEJHVSA-N |
|
|
评论 |
|---|